Sign inCreate account

Report workspace tools

NCT00158548COMPLETEDanonymous

Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

Sponsor

Source record

London School of Hygiene and Tropical Medicine

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

SP, chloroquine, amodiaquine, primaquine, artesunate

Indication / condition

AI-normalized

Malaria

Intervention

Source record

SP, chloroquine, amodiaquine, primaquine, artesunate

Source & freshness

Source record

NCT ID

NCT00158548

Original source

ClinicalTrials.gov

Source last updated

Jan 12, 2017

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00158548

Title

Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

Sponsor

London School of Hygiene and Tropical Medicine

Status

COMPLETED

Phase

PHASE3

Condition raw

Malaria, Falciparum Malaria, Vivax Malaria

Condition normalized

Malaria, Falciparum Malaria, Vivax Malaria

Modality raw

small molecule

Modality normalized

small molecule

Target raw

SP, chloroquine, amodiaquine, primaquine, artesunate

Target normalized

SP, chloroquine, amodiaquine, primaquine, artesunate

Interventions

SP, chloroquine, amodiaquine, primaquine, artesunate

Public preview

Source record

Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00158548

Status

COMPLETED

Phase

PHASE3

Sponsor

London School of Hygiene and Tropical Medicine

Executive brief

Investment-Ready Snapshot

Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 12, 2017
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00158548

Indication

Malaria

Modality

small molecule

Target

SP, chloroquine, amodiaquine, primaquine, artesunate

Intervention

SP, chloroquine, amodiaquine, primaquine, artesunate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.